Table 3.
Ongoing clinical trials of immune checkpoint therapy combined with novel strategies in hepatocellular carcinoma
| Conditions | Strategies | Phases | Enrollment | Study Designs | NCT Number | Status |
|---|---|---|---|---|---|---|
| Solid tumors (including HCC) | Pembrolizumab + p53MVA vaccine (vaccine therapy) | Phase 1 | 19 | Single Group Assignment | NCT02432963 | Active, not recruiting |
| HCC | Pembrolizumab + Talimogene Laherparepvec (gene therapy) | Phase 1 | 244 | Non-Randomized | NCT02509507 | Recruiting |
| HCC | Pembrolizumab + elbasvir/grazoprevir (antiviral therapy) + ribavirin (antiviral therapy) | Phase 1/2 | 30 | Non-Randomized | NCT02940496 | Active, not recruiting |
| HCC | Nivolumab + Pexastimogene Devacirepvec (vaccinia virus-based therapy) | Phase 1/2 | 30 | Single Group Assignment | NCT03071094 | Active, not recruiting |
| Liver, pancreatic, bile duct, or gallbladder cancer | Durvalumab + guadecitabine (DNMTi) | Phase 1 | 90 | Single Group Assignment | NCT03257761 | Recruiting |
| Solid tumors (including HCC) | FT500 (NK cell replacement) + nivolumab/pembrolizumab/atezolizumab | Phase 1 | 76 | Non-Randomized | NCT03841110 | Recruiting |
| HCC or Liver dominant metastatic cancer | Nivolumab + tadalafil + vancomycin | Phase 2 | 27 | Single Group Assignment | NCT03785210 | Recruiting |
| Solid tumors (including HCC) | Nivolumab/pembrolizumab + metformin (metabolic modulator), nivolumab/pembrolizumab + rosiglitazone (metabolic modulator) | Phase 2 | 108 | Randomized | NCT04114136 | Not yet recruiting |
DNMTi: DNA methyltransferase inhibitors; HCC: Hepatocellular carcinoma; p53MVA vaccine: Modified vaccinia virus Ankara vaccine expressing p53.